期刊文献+
共找到9篇文章
< 1 >
每页显示 20 50 100
慢性乙型肝炎抗-HBe阳性与HBV-DNA检出关系分析 被引量:1
1
作者 黄丹文 周水英 《浙江临床医学》 2002年第2期94-95,共2页
目的 分析慢性乙型肝炎抗 -HBe阳性与HBV -DNA检出关系。方法 采用斑点杂交法检测101例抗 -HBe阳性的慢性乙型肝炎患者HBV -DNA。结果 HBV -DNA阳性36例 ,阳性率35.64% ,HBV -DNA阳性检出率 ,以慢性重型肝炎最高 ,其次慢性乙型肝炎重度... 目的 分析慢性乙型肝炎抗 -HBe阳性与HBV -DNA检出关系。方法 采用斑点杂交法检测101例抗 -HBe阳性的慢性乙型肝炎患者HBV -DNA。结果 HBV -DNA阳性36例 ,阳性率35.64% ,HBV -DNA阳性检出率 ,以慢性重型肝炎最高 ,其次慢性乙型肝炎重度、中度患者 ,轻度慢性乙型肝炎最低。检出率随着病程的延长而升高。 结论 表明抗 -HBe阳转 ,体内HBV -DNA并未彻底清除 ,HBV的持续存在是变异发生的基础。 展开更多
关键词 hbv -HBE hbv-DNA 慢性乙型肝炎 斑点杂交法
下载PDF
Anti-HBV effect of liposome-encapsulated matrine in vitro ana in vivo 被引量:12
2
作者 Chang-QingLi Yu-TongZhu +4 位作者 Feng-XueZhang Lin-ChunFu Xiao-HuiLi YiCheng Xiang-YangLi 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第3期426-428,共3页
AIM: To study the anti-HBV effect of liposome-encapsulated matrine (Lip-M) in vitro and in vivo. METHODS: 2.2.15 cell line was cultured in vitro observe the effect of Lip-M and matrine on the secretion of HBsAg and HB... AIM: To study the anti-HBV effect of liposome-encapsulated matrine (Lip-M) in vitro and in vivo. METHODS: 2.2.15 cell line was cultured in vitro observe the effect of Lip-M and matrine on the secretion of HBsAg and HBeAg. The toxicity of Lip-M and matrine to 2.2.15 cell line was also studied by MTT method. In in vivo study, drug treatment experiment was carried out on the 13th day after ducks were infected with duck hepatitis B virus (DHBV). The ducks were randomly divided into 4 groups with 5-6 ducks in each group. Lip-M and matrine were given to DHBV-infected ducks respectively by gastric perfusion. Four groups were observed: group of Lip-M (20 mg/kg), group of Lip-M (10 mg/kg), group of matrine (20 mg/kg) and group of blank model. The drug was given once daily for 20 d continuously, and normal saline was used as control. The blood was drawn from the posterior tibial vein of all ducks before treatment (T0), after the medication for 5 (T5), 10 (T10), 15 (T15), 20 (T20) d and withdrawl of the drug for 3 d (P3). The serum samples were separated and stored at -70 ℃, DHBV-DNA was detected by the dot-blot hybridization. RESULTS: After addition of Lip-M and matrine to 2.2.15 cell line for eleven d, the median toxic concentration (TC50) of Lip-M and matrine was 7.29 mg/mL and 1.33 mg/mL respectively. The median concentration (IC50) of Lip-M to inhibit HBsAg and HBeAg expression was 0.078 mg/mL and 3.35 mg/mL respectively. The treatment index (TI) value of Lip-M for HBsAg and HBeAg was 93.46 and 2.17 respectively, better than that of matrine. The DHBV-infected duck model treatment test showed that the duck serum DHBV-DNA levels were markedly reduced in the group of Lip-M (20 mg/kg) after treated by gastric perfusion for 10, 15 and 20 d (0.43±0.22 vs 0.95±0.18, t = 4.70, P= 0.001<0.01.0.40±0.12 vs 0.95±0.18, t = 6.34, P= 0.000<0.01. 0.22±0.10 vs 0.95±0.18, t = 8.30, P= 0.000<0.01), compared to the group of matrine (20 mg/kg) (0.43±0.22 vs 0.79±0.19, t = 3.17, P= 0.01<0.05. 0.40±0.12 vs 0.73±0.24, t = 3.21, P= 0.009<0.05. 0.22±0.10 vs0.55±0.32, t = 2.27, P= 0.046<0.05.), and the control (0.43±0.22 vs50.98±0.29, t = 3.68, P = 0.005<0.01. 0.40±0.12 vs 0.97±0.30, t = 4.26, P= 0.002<0.01. 0.22±0.10 vs 0.95±0.27, t = 5.76, P= 0.000<0.01). After the treatment for 20 d and withdrawl of the drug for 3 d, duck serum DHBV-DNA level in the group of Lip-M (10 mg/kg) markedly reduced (0.56±0.26 vs0.95±0.38, t = 5.26, P= 0.003<0.05. 0.55±0.25 vs 0.95±0.38, t = 5.52, P= 0.003<0.05), and the difference was significant as compared with the control (0.56±0.26 vs 0.95±0.27, t = 2.37, P = 0.042<0.05. 0.55±0.25 vs 0.89±0.18, t = 2.55, P= 0.031<0.05), but not significant as compared with the group of matrine (20 mg/kg). After withdrawl of the drug for 3 d, the levels of DHBV-DNA did not relapse in both groups of Lip-M. CONCLUSION: Lip-M can evidently inhibit the replication of hepatitis B virus In vitro and in viva, its anti-HBV effect is better than that of matrine. 展开更多
关键词 Duck hepatitis B virus MATRINE LIPOSOME Virus Replications
下载PDF
Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues 被引量:8
3
作者 Zhuo-Lun Song Yu-Jun Cui +2 位作者 Wei-Ping Zheng Da-Hong Teng Hong Zheng 《World Journal of Gastroenterology》 SCIE CAS CSCD 2012年第48期7149-7157,共9页
Nucleos(t)ide analogues(NA) are a breakthrough in the treatment and management of chronic hepatitis B.NA could suppress the replication of hepatitis B virus(HBV) and control the progression of the disease.However,drug... Nucleos(t)ide analogues(NA) are a breakthrough in the treatment and management of chronic hepatitis B.NA could suppress the replication of hepatitis B virus(HBV) and control the progression of the disease.However,drug resistance caused by their long-term use becomes a practical problem,which influences the long-term outcomes in patients.Liver transplantation is the only choice for patients with HBV-related end-stage liver disease.But,the recurrence of HBV after transplantation often caused by the development of drug resistance leads to unfavorable outcomes for the recipients.Recently,the multi-drug resistance(MDR) has become a common issue raised due to the development and clinical application of a variety of NA.This may complicate the antiviral therapy and bring poorly prognostic outcomes.Although clinical evidence has suggested that combination therapy with different NA could effectively reduce the viral load in patients with MDR,the advent of new antiviral agents with high potency and high genetic barrier to resistance brings hope to antiviral therapy.The future of HBV researches relies on how toprevent the MDR occurrence and develop reasonable and effective treatment strategies.This review focuses on the diagnostic and therapeutic progress in MDR caused by the anti-HBV NA and describes some new research progress in this field. 展开更多
关键词 Hepatitis B virus Multi-drug resistance Nucleos(t)ide analogues Gene mutation Liver transplantation
下载PDF
乙肝病毒前S1抗原与几种乙肝指标的比较 被引量:6
4
作者 谢华 覃桂芳 +3 位作者 郭志红 王少平 陈卫东 夏莉 《广西医学》 CAS 2003年第8期1367-1369,共3页
目的 :探讨前 S1抗原 (Pre- S1)在乙肝诊断中的作用。方法 :用 EL ISA检测 15 3例急、慢性乙肝、乙肝病毒携带者的Pre- S1、抗 HBCIg M、HBVM,并进行比较 ;用荧光定量聚合酶链反应 (FQ- PCR)检测其中 10 6例的 HBVDNA,并以 HBVDNA为金标... 目的 :探讨前 S1抗原 (Pre- S1)在乙肝诊断中的作用。方法 :用 EL ISA检测 15 3例急、慢性乙肝、乙肝病毒携带者的Pre- S1、抗 HBCIg M、HBVM,并进行比较 ;用荧光定量聚合酶链反应 (FQ- PCR)检测其中 10 6例的 HBVDNA,并以 HBVDNA为金标准 ,对该 10 6例的 Pre- S1及 HBe Ag进行诊断性试验评价。结果 :在急性乙肝中 Pre- S1与抗 HBCIg M的差异有显著性 (P<0 .0 5 ) ;Pre- S1的敏感度 (se)为 94 .2 % ,特异性 (sp)为 90 .7% ,准确度 (accuracy)为 92 .5 % ,高于 HBe Ag的 se 84 .2 % ,sp6 7.6 % ,accuracy 73.6 %。而误诊率α为 0 .0 93,漏诊率β为 0 .0 5 8,低于 HBe Ag的α 0 .32 4 ,β 0 .15 8。结论 :Pre- S1快速 ,准确 ,简便 ,经济 。 展开更多
关键词 乙型肝炎 诊断 乙肝病毒前S1 酶联免疫吸附试验 HBCIgM hbvM
下载PDF
Lower baseline ALT cut-off values and HBV DNA levels better differentiate HBeAg(-) chronic hepatitis B patients from inactive chronic carriers 被引量:7
5
作者 Nimer Assy Zaza Beniashvili +3 位作者 Agness Djibre Gattas Nasser Maria Grosovski William Nseir 《World Journal of Gastroenterology》 SCIE CAS CSCD 2009年第24期3025-3031,共7页
AIM: To determine whether new cut-off values for aianine aminotransferase (ALT) and baseline hepatitis B virus (HBV) DNA levels better differentiate HBeAg(-) chronic hepatitis B (CriB) patients from inactive ... AIM: To determine whether new cut-off values for aianine aminotransferase (ALT) and baseline hepatitis B virus (HBV) DNA levels better differentiate HBeAg(-) chronic hepatitis B (CriB) patients from inactive chronic carriers. METHODS: Ninety-one patients [32 HBeAg(+) CriB, 19 inactive carriers and 40 HBeAg(-) CriB] were followed up for 2 years and were tested for HBV DNA levels by a PCR-based assay. ALT was tested twice during the last 6 mo using new cut-off values: ULN (upper limit of normal) 30 IU/L for males, 19 IU/L for females. Diagnostic accuracy, sensitivity, specificity, positive and negative predictive values were calculated by discriminant analysis. RESULTS: When using the revised ALT cut-off values, the lowest optimal HBV DNA level that differentiated HBeAg(-) CHB patients from inactive carriers was 50000 copies/mL. The diagnostic accuracy of HBV DNA to determine inactive carriers with a cut-off of 50000 copies/mL was similar to the previously recommended cut-off of 100000 copies/mL (91%). HBV DNA levels were lower than the cut-off value in 95% of inactive carriers and in 28% of HBeAg(-) CHB patients. With ALT 〈 30 IU/L in men and 〈 19 IU/L in women and HBV DNA levels 〈 100000 copies/mL, the risk of CHB is 5%. On the other hand, if ALT values were 〉 30 IU in men and 〉 19 IU in women and baseline HBV DNA levels were 〉 100000 copies/mL, the risk is 86%. CONCLUSION: New cut-off values for ALT together with HBV DNA levels proposed by AASLD (American Association for the Study of Liver Diseases) and NIH (National Institute of Health) consensus seem appropriate to characterize inactive carriers. 展开更多
关键词 Alanine aminotransferase Chronic hepatitis B Hepatitis B antigens Viral DNA
下载PDF
Quantitation of HBsAg predicts response to entecavir therapy in HBV genotype C patients 被引量:8
6
作者 Etsuro Orito Kei Fujiwara +3 位作者 Hiroshi Kanie Tesshin Ban Tomonori Yamada Katsumi Hayashi 《World Journal of Gastroenterology》 SCIE CAS CSCD 2012年第39期5570-5575,共6页
AIM: To analysis the factors that predict the response to entecavir therapy in chronic hepatitis patients with hepatitis B virus (HBV) genotype C. METHODS: Fifty patients [hepatitis B e antigen (HBeAg)- negative... AIM: To analysis the factors that predict the response to entecavir therapy in chronic hepatitis patients with hepatitis B virus (HBV) genotype C. METHODS: Fifty patients [hepatitis B e antigen (HBeAg)- negative:HBeAg-positive = 26:24] with HBV genotype C, who received nalve entecavir therapy for 〉 2 years, were analyzed. Patients who showed HBV DNA levels ≥ 3.0 log viral copies/mL after 2 years of entecavir ther- apy were designated as slow-responders, while those that showed 〈 3.0 log copies/mL were termed rapid- responders. Quantitative hepatitis B surface antigen (HBsAg) levels (qHBsAg) were determined by the Archi- tect HBsAg QT immunoassay. Hepatitis B core-related antigen was detected by enzyme immunoassay. Pre-C and Core promoter mutations were determined using by polymerase chain reaction (PCR). Drug-resistance muta- tions were detected by the PCR-Invader method. RESULTS: At year 2, HBV DNA levels in all patients in the HBeAg-negative group were 〈 3.0 log copies/mL. In contrast, in the HBeAg-positive group, 41.7% were slow-responders, while 58.3% were rapid-responders. No entecavir-resistant mutants were detected in the slow-responders. When the pretreatment factors were compared between the slow- and rapid-responders; the median qHBsAg in the slow-responders was 4.57 log IU/mL, compared with 3.63 log IU/mL in the rapid- responders (P 〈 0.01). When the pretreatment factors predictive of HBV DNA-negative status at year 2 in all 50 patients were analyzed, HBeAg-negative status, low HBV DNA levels, and low qHBsAg levels were signifi- cant (P 〈 0.01). Multivariate analysis revealed that the low qHBsAg level was the most significant predictive factor (P = 0.03). CONCLUSION: Quantitation of HBsAg could be a use- ful indicator to predict response to entecavir therapy. 展开更多
关键词 Chronic hepatitis B Quantitation of hepa-titis B surface antigen ENTECAVIR Hepatitis B virusgenotype C SIow-responders Hepatitis B core-relatedantigen Core promoter mutation Pre-C mutation
下载PDF
脾动脉部分栓塞术联合阿德福韦酯治疗乙型肝炎肝硬化脾功能亢进80例临床观察 被引量:3
7
作者 李艺 《陕西医学杂志》 CAS 2009年第7期866-867,共2页
目的:观察脾动脉部分栓塞术(PSE)联合阿德福韦酯治疗乙型肝炎肝硬化脾功能亢进患者的临床疗效。方法:80例患者随机分为两组,对照组36例给予基础保肝、维生素C、血制品等,并根据病情给予奥曲肽、奥美拉唑、利尿剂、抗感染等对症综合治疗... 目的:观察脾动脉部分栓塞术(PSE)联合阿德福韦酯治疗乙型肝炎肝硬化脾功能亢进患者的临床疗效。方法:80例患者随机分为两组,对照组36例给予基础保肝、维生素C、血制品等,并根据病情给予奥曲肽、奥美拉唑、利尿剂、抗感染等对症综合治疗;治疗组44例在以上常规治疗基础上行PSE,加服阿德福韦酯。结果:治疗组外周血白细胞、血小板、肝功能持续改善,HBeAg/抗-HBe转换、HBV-DNA转阴、肝纤维化改善等方面均优于对照组。结论:PSE联合阿德福韦酯治疗乙型肝炎肝硬化脾功能亢进,能提高患者生存质量,延长生存期。 展开更多
关键词 肝炎 乙型/治疗 肝硬化/治疗 脾功能亢进/治疗 栓塞 治疗性 @抗hbv 核苷类似物
下载PDF
Management of chronic hepatitis B in pregnancy 被引量:16
8
作者 Guo-Rong Han Chuan-Lu Xu +1 位作者 Wei Zhao Yong-Feng Yang 《World Journal of Gastroenterology》 SCIE CAS CSCD 2012年第33期4517-4521,共5页
Pregnancy associated with chronic hepatitis B (CHB) is a common and important problem with unique challenges. Pregnant women infected with CHB are different from the general population, and their special problems need... Pregnancy associated with chronic hepatitis B (CHB) is a common and important problem with unique challenges. Pregnant women infected with CHB are different from the general population, and their special problems need to be considered: such as the effect of hepatitis B virus (HBV) infection on the mother and fetus, the effect of pregnancy on replication of the HBV, whether mothers should take HBV antiviral therapy during pregnancy, the effect of these treatments on the mother and fetus, how to carry out immunization of neonates, whether it can induce hepatitis activity after delivery and other serious issues. At present, there are about 350 million individuals with HBV infection worldwide, of which 50% were infected during the perinatal or neonatal period, especially in HBV-endemic countries. Currently, the rate of HBV infection in thechild-bearing age group is still at a high level, and the infection rate is as high as 8.16%. Effective prevention of mother-to-child transmission is an important means of reducing the global burden of chronic HBV infection. Even after adopting the combined immunization measures, there are still 5%-10% of babies born with HBV infection in hepatitis B e antigen positive pregnant women. As HBV perinatal transmission is the main cause of chronic HBV infection, we must consider how to prevent this transmission to reduce the burden of HBV infection. In this population of chronic HBV infected women of childbearing age, specific detection, intervention and follow-up measures are particularly worthy of attention and discussion. 展开更多
关键词 Chronic hepatitis B Hepatitis B virus Mother-to-child transmission Perinatal transmission Pregnancy Vertical transmission Antiviral therapy
下载PDF
Green tea polyphenol, epigallocatechin-3-gallate, possesses the antiviral activity necessary to fight against the hepatitis B virus replication in vitro 被引量:9
9
作者 Jing-yao PANG Kui-jun ZHAO +2 位作者 Jia-bo WANG Zhi-jie MA Xiao-he XIAO 《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》 SCIE CAS CSCD 2014年第6期533-539,共7页
Although several antiviral drugs and vaccines are available for use against hepatitis B virus (HBV), hepatitis caused by HBV remains a major public health problem worldwide, which has not yet been resolved, and new ... Although several antiviral drugs and vaccines are available for use against hepatitis B virus (HBV), hepatitis caused by HBV remains a major public health problem worldwide, which has not yet been resolved, and new anti-HBV drugs are in great demand. The present study was performed to investigate the anti-HBV activity of epigallocatechin- 3-gallate (EGCG), a natural-origin compound, in HepG2 2.2.15 cells. The antiviral activity of EGCG was examined by detecting the levels of HBsAg and HBeAg in the supematant and extracellular HBV DNA. EGCG effectively suppressed the secretion of HBsAg and HBeAg from HepG2 2.2.15 cells in a dose- and time-dependent manner, and it showed stronger effects at the level of 0.11-0.44 pmol/ml (50-200 μg/ml) than lamivudine (3TC) at 0.87 μmol/ml (200 pg/ml). EGCG also suppressed the amount of extracellular HBV DNA. The data indicated that EGCG possessed anti-HBV activity and suggested the potential of EGCG as an effective anti-HBV agent with low toxicity. 展开更多
关键词 Epigallocatechin-3-gallate Hepatitis B virus hbv Antiviral activity HepG2 2.2.15 LAMIVUDINE
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部